An Alternatively Spliced Gain-of-Function NT5C2 Isoform Contributes to Chemoresistance in Acute Lymphoblastic Leukemia
Manuel Torres-Diz(Children's Hospital of Philadelphia), Andrei Thomas‐Tikhonenko(Children's Hospital of Philadelphia)
Cited by 0
Related Papers
CD19 is a major B cell receptor–independent activator of MYC-driven B-lymphomagenesis
|Journal of Clinical Investigation|2012|95
Alternative splicing of its 5′-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies
|Blood|2023|43
Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma
|Leukemia|2019|29
An Alternatively Spliced Gain-of-Function NT5C2 Isoform Contributes to Chemoresistance in Acute Lymphoblastic Leukemia
|Cancer Research|2024|10
MYC hyperactivates WNT signaling in APC/CTNNB1-mutated colorectal cancer cells through miR-92a-dependent repression of DKK3
|bioRxiv (Cold Spring Harbor Laboratory)|2021|0